CARIS LIFE SCIENCES, INC. vs NATERA, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CAI and NTRA diverge most: on operating margin, CAI reads 10.2% and NTRA reads -10.1%; on return on invested capital, CAI reads 3.8% and NTRA reads -11.1%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | CAI | NTRA |
|---|---|---|
| Price | $29.66 | $400.47 |
| Market cap | $8.4B | $57.4B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| Implied growth (priced in) | +36.7% | — |
| P/B | 14.18 | 31.50 |
| P/S | 9.56 | 21.20 |
| EV/EBITDA | 116.0 | — |
| Revenue growth | +79.7% | +37.8% |
| Operating margin | 10.2% | -10.1% |
| Net margin | -5.5% | -7.1% |
| Return on equity | -8.2% | -10.6% |
| Return on assets | -4.0% | -7.2% |
| Return on invested capital | 3.8% | -11.1% |
| FCF yield | 1.5% | 0.1% |
| Debt / equity | 0.66 | 0.04 |
| Current ratio | 5.53 | 3.00 |
| Altman Z (solvency) | 4.73 | 5.88 |
| Piotroski F (quality) | 6 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.